After the Sept. 11 attacks, the US considered immunizing the whole population to guard against a terrorist attack using smallpox. “In the long run, it was decided no, due to the negative consequences of vaccinating plenty of people,” said Bill Hanage, an epidemiologist on the Harvard T.H. Chan School of Public Health.
“Vaccine uncomfortable side effects are rare,” he added. “But once you begin giving it to tens of millions of individuals, then they’ll start so as to add up.”
Newer generation vaccines like Jynneos are more likely to be safer for big groups, and ring vaccination could also be enough to contain the virus. “Hopefully, presumably, monkeypox continues to be relatively rare straight away, and a hoop vaccination strategy might give you the chance to maintain it completely at bay,” Dr. Hanage said.
Along with vaccines for prevention, the US has procured greater than two million doses of an antiviral pill called tecovirimat, which is approved to treat smallpox in those that turn out to be infected, in line with the C.D.C. The agency can be working with the drug’s manufacturer to develop an intravenous form.
Human monkeypox was first identified in 1970 in a 9-year-old boy in a region of the Democratic Republic of Congo where smallpox had been eliminated. Monkeypox cases within the country have significantly increased within the many years since smallpox mass vaccination ended.
In 2003, the US recorded dozens of monkeypox cases that were traced to infected pets. Although the virus was first discovered in 1958 in monkeys kept for research purposes, it’s spread by rodents.
Per week to 2 weeks after exposure, infected people may begin to experience fever, sore throat, cough, fatigue and body aches. Additionally they develop a definite rash, first on the face, then on the palms of the hand and soles of the feet, after which all around the body. The lesions blister, grow and fill with a white puslike substance.